Who can have Mounjaro on the NHS — and what happens if you don't qualify yet

The current NHS threshold: BMI, conditions, and how many you need

NICE approved tirzepatide for NHS use in England in December 2024, but access is not open to everyone at once. The rollout is structured in cohorts, each one unlocking a slightly broader group.

Right now, you can access Mounjaro on the NHS if you have a BMI of 40 or above and four or more of the five qualifying conditions: high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. If you want a detailed breakdown of who can get Mounjaro on the NHS and exactly how each qualifying condition is defined, that criteria page covers it in full. A single condition alongside a high BMI is not enough at this stage.

The second cohort opened on 23 June 2026, extending eligibility to adults with a BMI between 35 and 39.9 who also have four or more of those same conditions. A further expansion is planned from around March 2027, covering BMI of 40 or above with three qualifying conditions rather than four.

Throughout all phases, lower BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds: the headline BMI figure drops by 2.5 kg/m² in each case. You can use the NHS BMI calculator to check where your own figure sits before speaking to a GP.

Even meeting these criteria does not guarantee a prescription today. Participation in the new GP contract is optional, so access varies by practice and area. Every patient accessing Mounjaro through the NHS must also take part in structured dietary and activity support alongside treatment.

Why the decision is harder than a simple BMI check

If you are near but not quite at the current threshold (say, three qualifying conditions rather than four, or a BMI of 33) you may be wondering whether to wait, or to explore whether any other route is open to you. That is the real decision this page is about.

Waiting has an honest cost. The criteria will widen, but not quickly: the gap between cohort one (mid-2025) and the next planned expansion (late 2027) is roughly two years. Long NHS specialist waiting lists for Wegovy under TA875 give some indication of how demand versus capacity plays out in practice.

There is also the question of what private access to Mounjaro actually involves. The licensed private eligibility criteria are different from the NHS ones. Any adult with a BMI of 30 or above, or 27 or above with at least one weight-related condition, may be assessed for a private prescription, the prescriber then reviews the full clinical picture. You do not need four comorbidities. The conditions that make someone eligible for the NHS version are relevant context, but they are not the gate.

Private treatment is not the NHS. It carries a cost, and what that cost actually covers varies significantly between providers. Mounjaro is a prescription-only medicine, and a common question is who can prescribe Mounjaro in the first place, whether through the NHS or a private route; any legitimate supply requires a clinical assessment by a qualified prescriber, whatever the route.

From GP referral to specialist service: the NHS pathway in full

If you do meet the current NHS criteria, the practical route starts with your GP. Under the 2026/27 GP contract, practices that have opted in can prescribe tirzepatide directly in primary care, with wraparound dietary and activity support as part of the package. Not every practice has opted in, it is worth asking your own GP directly rather than assuming either way.

If your practice has not opted in, or you are referred into a specialist weight management service, timescales lengthen further. NHS England's guidance on weight management injections sets out what wraparound care should look like and what patients can reasonably expect from the service.

Scotland, Wales, and Northern Ireland operate separate systems with different thresholds and timescales. If you are not in England, check with your local health board for the criteria that apply to you.

For people who want to understand when the NHS criteria are likely to reach their situation, the phased timeline above is the best current guide. Criteria, cohort dates, and local implementation can all shift, so checking directly with your GP remains the only reliable way to confirm your position. If you are still unsure whether you qualify at all, our page on whether you can get Mounjaro on the NHS walks through the eligibility questions in a more practical way.

What a private route looks like if the NHS is not yet available to you

A clinician-led online pharmacy can assess you for a private Mounjaro prescription without a GP referral or waiting list. At nume, a GPhC-registered Independent Prescriber reviews every consultation personally, the same day it is submitted. There is no algorithm making the decision. If the prescriber confirms you are clinically suitable, treatment is dispatched the same day for orders placed before 12pm Monday to Friday, and your pen arrives with DPD tracked delivery the next working day in plain, unbranded packaging.

It is a prescription-only medicine regardless of the route. Suitability is assessed each time, including at every repeat order, not just at the start. Our clinical team can answer questions about your specific situation during that process.

If you are ready to check whether you qualify privately, you can speak to our prescribers through a free consultation with no obligation to proceed.